Article
Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study.
Molecular psychiatry - 1 Jun 2026
Ho Ada Man-Choi, Coombes Brandon J, Batzler Anthony, Pazdernik Vanessa K, Pendegraft Richard S, Skime Michelle, Bendjemaa Narjes, Carpiniello Bernardo, Contu Martina, Dalkner Nina, Fellendorf Frederike T, Fico Giovanna, Fullerton Claudio D, Gardea-Resendez Manuel, Gonzalez-Garza Sarai, Jaafari Nematollah, Jiménez Esther, Kebir Oussama, Legrand Adrien, Luna-Garza Sofia, Meloni Anna, Millet Bruno, Mouaffak Fayçal, Nunes Abraham, O'Donovan Claire, Paribello Pasquale, Pinna Marco, Pisanu Claudia, Pomarol-Clotet Edith, Romo-Nava Francisco, Sánchez Raúl F, Scott Katie, Squassina Alessio, Vilella Elisabet, Serretti Alessandro, Prieto Miguel L, Reininghaus Eva Z, Bengesser Susanne A, Cuellar-Barboza Alfredo B, Krebs Marie-Odile, Chaumette Boris, Vieta Eduard, Manchia Mirko, McElroy Susan L, Alda Martin, Frye Mark A, Biernacka Joanna M
Abstract excerpt
Identifying biological and clinical factors associated with response to mood-stabilizing medications is critical for improving bipolar disorder (BD) treatment. The Mood Stabilizer Genomics (MoStGen) Consortium was established to investigate pharmacogenomic and clinical predictors of response to treatment of BD with antiepileptic drug mood stabilizers (AMS). Here we present the first pharmacogenomic analyses of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.